Key facts
- Frazier Life Sciences Public Fund, L.P. filed SCHEDULE 13G/A for Lexeo Therapeutics, Inc. Common Stock, $0.0001 par value per share (LXEO).
- Disclosed ownership: 5.1%.
- Date of event: 31 Dec 2025.
Frazier Life Sciences Public Fund, L.P. - 31 Dec 2025 SCHEDULE 13G/A Report for Lexeo Therapeutics, Inc. Common Stock, $0.0001 par value per share (LXEO)
- Filing manager
- Frazier Life Sciences Public Fund, L.P.
- Reporting owner
- Frazier Life Sciences Public Fund, L.P.
- Symbol
- LXEO
- Shares outstanding
- 72,515,118 shares
- Disclosed shares
- 3,698,271 shares
- Ownership percentage
- 5.1%
- Form type
- SCHEDULE 13G/A
- Filing time
- 13 Feb 2026, 17:33:55 UTC
- Event date
- 31 Dec 2025
- Previous filing
- 14 Aug 2025
- SEC filing
- View on sec.gov
Reporting parties
Subject security
Ownership signal
SEC evidence
Key filing fact
Frazier Life Sciences Public Fund, L.P. disclosed 5.1% ownership in Lexeo Therapeutics, Inc. Common Stock, $0.0001 par value per share (LXEO) on 31 Dec 2025.
Change
- Previous schedule filing date: 14 Aug 2025.
- Current filing was accepted on 13 Feb 2026, 17:33.
Research use
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Reporting managers (14)
Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Frazier Life Sciences Public Fund, L.P. | 5.1% | 3,698,271 | 0 | 3,698,271 | /s/ Jennifer Martin | By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P. | |
| FHMLSP, L.P. | 5.1% | 3,698,271 | 0 | 3,698,271 | /s/ Jennifer Martin | By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P. | |
| FHMLSP, L.L.C. | 5.1% | 3,698,271 | 0 | 3,698,271 | /s/ Jennifer Martin | By Jennifer Martin, CFO of FHMLSP, L.L.C. | |
| Frazier Life Sciences X, L.P. | 0.1% | 87,424 | 0 | 87,424 | /s/ Jennifer Martin | By Jennifer Martin, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P. | |
| FHMLS X, L.P. | 0.1% | 87,424 | 0 | 87,424 | /s/ Jennifer Martin | By Jennifer Martin, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P. | |
| FHMLS X, L.L.C. | 0.1% | 87,424 | 0 | 87,424 | /s/ Jennifer Martin | By Jennifer Martin, CFO of FHMLS X, L.L.C. | |
| Frazier Life Sciences XI, L.P. | 0.3% | 232,784 | 0 | 232,784 | /s/ Jennifer Martin | By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P. | |
| FHMLS XI, L.P. | 0.3% | 232,784 | 0 | 232,784 | /s/ Jennifer Martin | By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P. | |
| FHMLS XI, L.L.C. | 0.3% | 232,784 | 0 | 232,784 | /s/ Jennifer Martin | By Jennifer Martin, CFO of FHMLS XI, L.L.C. | |
| Frazier Life Sciences XII, L.P. | 0.6% | 406,246 | 0 | 406,246 | /s/ Jennifer Martin | By Jennifer Martin, CFO of FHMLS XII, L.L.C., GP of FHMLS XII, L.P., GP of Frazier Life Sciences XII, L.P. | |
| FHMLS XII, L.P. | 0.6% | 406,246 | 0 | 406,246 | /s/ Jennifer Martin | By Jennifer Martin, CFO of FHMLS XII, L.L.C., GP of FHMLS XII, L.P. | |
| FHMLS XII, L.L.C. | 0.6% | 406,246 | 0 | 406,246 | /s/ Jennifer Martin | By Jennifer Martin, CFO of FHMLS XII, L.L.C. | |
| James N. Topper | 0.1% | 87,424 | 0 | 87,424 | /s/ Jennifer Martin | By Jennifer Martin, Attorney-in-Fact for James N. Topper, pursuant to a Power of Attorney, a copy of which was filed with the SEC on January 27, 2026 | |
| Patrick J. Heron | 0.1% | 87,424 | 0 | 87,424 | /s/ Jennifer Martin | By Jennifer Martin, Attorney-in-Fact for Patrick Heron, pursuant to a Power of Attorney, a copy of which was filed with the SEC on January 27, 2026 |
CIK / CUSIP context first